The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Open accessAbstract
Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The “gatekeeper” T790M mutation is a well-characterized mechanism of acquired resistance to first- and second-generation TKIs, which has been reported to occur in >60% of cases.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the efficacy of EGFR TKIs in the first-line treatment of EGFRm+ NSCLC, acquired resistance to therapy occurs in the majority of patients.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common mechanism of resistance to first-generation EGFR TKIs is the development of the gatekeeper T790M mutation, which occurs in approximately 50–70% of patients.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In two patients with NSCLC for whom we were not able to identify a genomic resistance mechanism, we observed histologic transformation from adenocarcinoma to squamous-cell carcinoma, which suggests that nongenetic mechanisms of resistance to KRASG12C inhibition may occur, similar to those observed with other targeted therapies in lung cancer.24-26”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [25]
In the citing paper
“after using first-generation EGFR TKIs for approximately 9–14 months, almost all tumors progressed again.111”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [111]
In the citing paper
“the EGFR T790M gatekeeper mutation, is a leading cause of resistance to first- and second-generation EGFR inhibitors [11,12].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [12]
In the citing paper
“the histologic transformation of lung adenocarcinoma subtype to small cell carcinoma subtype, which accounts for 5–15% of EGFR-mutant lung cancer patients with acquired resistance to EGFR TKIs [12,17].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [12]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [12]
In the citing paper
“Similar phenomenon occurs in other targeted therapies for lung cancer [94, 140, 141].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [141]
In the citing paper
“Genomic sequencing of EGFR from both the baseline and repeated biopsy samples shows that a transformed SCLC tumour sample retained the original EGFR-activating mutation, suggesting that these were not de novo clones, but rather a transformed phenotype of pre-existing cancer cells.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [34]
In the citing paper
“Repeated bioptic sampling from patients with EGFR-mutant NSCLCs have shown a rare but consistent observation of histological transformation from adenocarcinoma to small cell lung cancer (SCLC).34”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [34]
In the citing paper
“However, patients with adenocarcinoma-SCLC transformation presented mixed responses to EGFR inhibitors, despite the persistency of the activating mutation, probably due to the loss of EGFR expression at the protein level.34”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [34]
In the citing paper
“Activation of other cell receptors such as FGFR1,2,351 or of cell signalling pathways such as BRAF (Val600Glu, Gly469Ala) mutation (1%)52 and PIK3CA mutation (5%)34, that play a key role in promoting the proliferation, survival, drug resistance of cancer cells, have been described.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [34]
In the citing paper
“A secondary epidermal growth factor receptor (EGFR) mutation, T790M, is the most common resistance mechanism in EGFR mutant adenocarcinomas that have progressed on erlotinib.”
In the citing paper
“These data are further supported by the clinical observations that EGFR mutant SCLCs are highly sensitive to SCLC chemotherapy regimens7.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“As reported previously, all of the resistant SCLC cancers harboured the original activating EGFR mutation7.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“Importantly, the tumours that transformed to SCLC harboured the original activating EGFR mutation, suggesting direct evolution from the initial cancer, rather than a distinct, second primary cancer.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“Both SCLC transformed samples harboured an activating mutation in PIK3CA, which we previously observed in SCLC transformed cases7”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“However, repeat biopsy studies have consistently suggested that the SCLC transformed cancers represent an evolution from the initial adenocarcinomas rather than a second coincident cancer, because the activating driver EGFR mutations are identical to the original adenocarcinomas in all cases.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“One unexpected finding from these studies was the discovery that 5–15% of patient tumours undergo transformation to SCLC histology upon acquisition of resistance.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“However, from a clinical perspective, we feel that it is unlikely that these SCLCs were present from the onset of the disease in a majority of these cases because when the SCLC surfaces in the clinic, it progresses quite rapidly (like classical SCLC)7.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“is most commonly due to the EGFR T790M mutation, present in approximately 50 to 60% of resistant cases.5,6”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [5]
In the citing paper
“Epithelial‐mesenchymal transition (EMT) has also been indicated as one mechanism of resistance to EGFR-TKIs[10].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [10]
In the citing paper
“At the time of progression, about 60% of patients (regardless of race or ethnic background) are found to have a p.Thr790Met point mutation (T790M) in the gene encoding EGFR.13–16”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [15]
In the citing paper
“Resistance to conventional EGFR-TKIs develops after a median of 10 to 12 months and is most commonly mediated by an acquired mutation, T790M1-5.”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [4]
In the citing paper
“with the EGFR T790M somatic mutation being the most frequent alteration detected in approximately half of progressing tumors.[14][15][16]”
In the citing paper
“Other resistance mechanisms involve bypass pathways such as MET proto-oncogene, receptor tyrosine kinase gene (MET) amplification (5%-30% depending on thresholds), erb-b2 receptor tyrosine kinase 2 (HER2) amplification (12%), phosphatidylinositol-4,5bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation (5%), and B-Raf proto-oncogene, serine/threonine kinase gene (BRAF) mutation (1%)”
In the citing paper
“the most common finding in EGFR-mutated tumours relapsing after first-/secondgeneration EGFR TKI therapy [19].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [19]
In the citing paper
“each initial EGFR sensitizing mutation is an early “truncal” event in the pathogenesis of lung adenocarcinoma, and previous studies have not detected significant heterogeneity across multiple biopsies (5,37).”
From Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses (2016) · cites this paper as [5]
In the citing paper
“Genomic heterogeneity within tumors and across metastatic tumor sites in the same patient is the major cause of treatment failure and emergence of therapy resistance (19).”
From Radiomics: Images Are More than Pictures, They Are Data (2016) · cites this paper as [19]
In the citing paper
“Accordingly, PIK3CA mutations have been identified in biopsies of EGFR mutant cancers with acquired resistance to EGFR inhibitors (Sequist et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Sequist et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“They have identified several resistance mechanisms, two of which—EGFR mutation T790M (6, 7) andMET amplification (8, 9)—have been validated in the clinic.”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,021
Menon, D. R., Hammerlindl, H., Torrano, J., Schaider, H., & Fujita, M. (2020) · Theranostics · doi:10.7150/thno.42523 · Cited by 57
Mahmoud, M. A., Mohammed, A. F., Salem, O. I. A., Gomaa, H. A. M., & Youssif, B. G. M. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200009 · Cited by 55
Criscione, S. W., Martin, M. J., Oien, D. B., Gorthi, A., Miragaia, R. J., Zhang, J., Chen, H., Karl, D. L., Mendler, K., Markovets, A. A., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00337-w · Cited by 57
Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1
Rodarte, K. E., Heyman, S. N., Guo, L. M., Flores, L., Savage, T. K., Villarreal, J., Deng, S., Xu, L., Shah, R. B., Oliver, T. G., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1388 · Cited by 55
Tang, Z.-H., Jiang, X., Guo, X., Fong, C. M. V., Chen, X., & Lu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13150 · Cited by 56
Fujii, T., Barzi, A., Bianchi, A. S., Cassingena, A., Siravegna, G., Karp, D. D., Piha-Paul, S. A., Subbiah, V., Tsimberidou, A. M., Huang, H. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2592 · Cited by 56
Gao, Y., Song, P., Li, H., Jia, H. M., & Zhang, B. (2017) · BMC Cancer · doi:10.1186/s12885-017-3474-3 · Cited by 55
Fan, P., Narzisi, G., Jayaprakash, A. D., Venturini, E., Robine, N., Smibert, P., Germer, S., Yu, H. A., Jordan, E., Paik, P. K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717782115 · Cited by 56
Yonesaka, K. (2021) · Cancers · doi:10.3390/cancers13051047 · Cited by 55
Caeser, R., Egger, J. V., Chavan, S. S., Socci, N. D., Jones, C. B., Kombak, F. E., Asher, M., Roehrl, M. H. A., Shah, N., Allaj, V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29794-4 · Cited by 56
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
Haratake, N., Ozawa, H., Morimoto, Y., Yamashita, N., Daimon, T., Bhattacharya, A., Wang, K., Nakashoji, A., Isozaki, H., Shimokawa, M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.017 · Cited by 54
Zhang, Y., Li, X., Tang, Y., Xu, Y., Guo, W., Li, Y., Liu, X., Huang, C., Wang, Y., & Wei, Y.-Q. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.005 · Cited by 54
What are we learning from the cancer genome?
Collisson, E. A., Cho, R. J., & Gray, J. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.159 · Cited by 55
Wang, X., Goldstein, D., Crowe, P. J., & Yang, J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94745 · Cited by 55
Ishibashi, M., Neri, S., Hashimoto, H., Miyashita, T., Yoshida, T., Nakamura, Y., Udagawa, H., Kirita, K., Matsumoto, S., Umemura, S., et al. (2017) · Scientific Reports · doi:10.1038/srep46662 · Cited by 54
Hochmair, M. J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0566-1 · Cited by 55
Berghoff, A. S., Bellosillo, B., Caux, C., Langen, A. J. D., Mazières, J., Normanno, N., Preusser, M., Provencio, M., Rojo, F., Wolf, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000498 · Cited by 56
Sehgal, K., Varkaris, A. S., Viray, H., VanderLaan, P. A., Rangachari, D., & Costa, D. B. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000697 · Cited by 54
Jin, Y., Bao, H., Le, X., Fan, X., Tang, M., Shi, X., Zhao, J., Yan, J., Xu, Y., Quek, K., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1104-z · Cited by 53
Kuo, M.-H., Lee, A.-C., Hsiao, S.-H., Lin, S., Chiu, Y.-F., Yang, L.-H., Yu, C.-C., Chiou, S., Huang, H., Ko, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3228 · Cited by 53
Sasaki, S., Yoshioka, Y., Ko, R., Katsura, Y., Namba, Y., Shukuya, T., Kido, K., Iwakami, S., Tominaga, S., & Takahashi, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.07.001 · Cited by 53
Fan, X., Li, N., Wu, J., Zhou, Y., He, J., Liu, L., & Leung, E. L. (2014) · Molecules · doi:10.3390/molecules19033508 · Cited by 53
Neal, J. W., & Nguyen, K.-S. H. (2012) · Biologics · doi:10.2147/btt.s26558 · Cited by 53
Nishino, M., Dahlberg, S. E., Cardarella, S., Jackman, D. M., Rabin, M. S., Hatabu, H., Janne, P. A., & Johnson, B. E. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318294c909 · Cited by 53
Tartarone, A., & Lerose, R. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815587820 · Cited by 54
Ou, S. I., Govindan, R., Eaton, K. D., Otterson, G. A., Gutierrez, M. E., Mita, A. C., Argiris, A. E., Brega, N. M., Usari, T., Tan, W., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.131 · Cited by 53
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
Jiang, W., & Ji, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.006 · Cited by 55
He, Y., Zhang, X., Jia, K., Dziadziuszko, R., Zhao, S., Deng, J., Wang, H., Hirsch, F. R., & Zhou, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.15 · Cited by 54
Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer
Guo, Y., Cao, R., Zhang, X., Huang, L., Sun, L., Zhao, J., Ma, J., & Han, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s230309 · Cited by 54
Hass, R., von der Ohe, J., & Ungefroren, H. (2020) · Cancers · doi:10.3390/cancers12123674 · Cited by 53
Jia, P., Jin, H., Meador, C. B., Xia, J., Ohashi, K., Liu, L., Pirazzoli, V., Dahlman, K. B., Politi, K. A., Michor, F., et al. (2013) · Genome Research · doi:10.1101/gr.152322.112 · Cited by 54
PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genesPreprint
Soto‐Feliciano, Y. M., Bartlebaugh, J. M. E., Liu, Y., Rivera, F. J. S., Bhutkar, A. J., Weintraub, A. S., Buenrostro, J. D., Cheng, C. S., Regev, A., Jacks, T., et al. (2017) · Genes & Development · doi:10.1101/gad.295857.117 · Cited by 53
Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non–Small-Cell Lung Cancer
Awad, M. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2777 · Cited by 56
Tripathi, S. K., Pandey, K., Rengasamy, K. R. R., & Biswal, B. K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21700 · Cited by 54
Lineage Plasticity: The New Cancer Hallmark on the Block
Mehta, A., & Stanger, B. Z. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1067 · Cited by 54
Paik, P. K., Varghese, A. M., Sima, C. S., Moreira, A. L., Ladanyi, M., Kris, M. G., & Rekhtman, N. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0163 · Cited by 52
Verone-Boyle, A. R., Shoemaker, S. F., Attwood, K. M., Morrison, C. D., Makowski, A. J., Battaglia, S., & Hershberger, P. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6493 · Cited by 52
Sun, Z., Wang, Z., Liu, X., & Wang, D. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000172 · Cited by 53
Fustaino, V., Presutti, D., Colombo, T., Cardinali, B., Papoff, G., Brandi, R., Bertolazzi, P., Felici, G., & Ruberti, G. (2017) · Oncotarget · doi:10.18632/oncotarget.21132 · Cited by 52
Yamazaki, S., Higuchi, Y., Ishibashi, M., Hashimoto, H., Yasunaga, M., Matsumura, Y., Tsuchihara, K., Tsuboi, M., Goto, K., Ochiai, A., et al. (2018) · Cancer Science · doi:10.1111/cas.13624 · Cited by 52
Nakatani, K., Yamaoka, T., Ohba, M., Fujita, K., Arata, S., Kusumoto, S., Taki-Takemoto, I., Kamei, D., Iwai, S., Tsurutani, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0591 · Cited by 55
Targeted therapies for small cell lung cancer: Where do we stand?
Arcaro, A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.03.001 · Cited by 51
ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer
Gerber, D. E., Oxnard, G., & Govindan, R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.91 · Cited by 51
Cellular dormancy in minimal residual disease following targeted therapy
Ruth, J. R., Pant, D. K., Pan, T.-C., Seidel, H. E., Baksh, S. C., Keister, B. A., Singh, R., Sterner, C. J., Bakewell, S. J., Moody, S. E., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01416-9 · Cited by 52
Hobor, S., Bakir, M. A., Hiley, C. T., Skrzypski, M. T., Frankell, A. M., Bakker, B., Watkins, T. B. K., Markovets, A. A., Dry, J. R., Brown, A. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47606-9 · Cited by 51
Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows
Tan, N., Li, Y., Ying, J., & Chen, W. (2024) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2024-0019 · Cited by 52
Arnedos, M., Vielh, P. R., Soria, J., & André, F. (2013) · The Journal of Pathology · doi:10.1002/path.4276 · Cited by 51
Xu, G., Yu, H., Shi, X., Sun, L., Zhou, Q., Zheng, D., Shi, H., Li, N., Zhang, X., & Shao, G. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-174 · Cited by 51
Smith, M. A., Hall, R. D., Fisher, K. J., Haake, S. M., Khalil, F. K., Schabath, M. B., Vuaroqueaux, V., Fiebig, H., Altiok, S., Chen, Y. A., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005906 · Cited by 51
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
Li, J., Bennett, K. L., Stukalov, A., Fang, B., Zhang, G., Yoshida, T., Okamoto, I., Kim, J., Song, L., Bai, Y., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.61 · Cited by 51
Martin, M. J., Eberlein, C., Taylor, M. A., Ashton, S. E., Robinson, D. M., & Cross, D. A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.13388 · Cited by 52
Ariyasu, R., Nishikawa, S., Uchibori, K., Oh‐hara, T., Yoshizawa, T., Dotsu, Y., Koyama, J., Saiki, M., Sonoda, T., Kitazono, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.12.018 · Cited by 51
written on behalf of AME Lung Cancer Cooperative Group, Liang, H., Pan, Z., Wang, W., Guo, C., Chen, D., Zhang, J., Zhang, Y., Tang, S., He, J., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.150 · Cited by 52
Koch, H., Busto, M. E. D. C., Kramer, K., Médard, G., & Küster, B. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00161 · Cited by 51
MASS SPECTROMETRY‐BASED PERSONALIZED DRUG THERAPY
Cui, J., Wang, L., Tan, Z., Zhou, H., Zhan, X., & Yin, J. (2020) · Mass Spectrometry Reviews · doi:10.1002/mas.21620 · Cited by 51
Wang, B., Kou, S., Lin, Z., Shi, J., & Liu, Y.-X. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.04.151 · Cited by 52
Cons: Can liquid biopsy replace tissue biopsy?—the US experience
Mino-Kenudson, M. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.08.01 · Cited by 51
Self-citationDeveloping biomarker-specific end points in lung cancer clinical trials
Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.222 · Cited by 51
Self-citationLiao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0305-9 · Cited by 52
Tanaka, K., Asahina, H., Kishimoto, J., Miyata, Y., Uchida, T., Watanabe, K., Hamai, K., Harada, T., Tsubata, Y., Sugawara, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.019 · Cited by 50
Koga, T., Suda, K., & Mitsudomi, T. (2022) · Cancer Science · doi:10.1111/cas.15263 · Cited by 50
Xu, Y., Yang, Y., Wang, Z., Sjöström, M., Jiang, Y., Tang, Y., Cheng, S., Deng, S., Wang, C., Gonzalez, J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0539 · Cited by 50
Alexander, P. B., & Wang, X. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0396-9 · Cited by 50
Yoshida, T., Yoh, K., Niho, S., Umemura, S., Matsumoto, S., Ohmatsu, H., Ohe, Y., & Goto, K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.025 · Cited by 50
Monica, S. L., Caffarra, C., Saccani, F., Galvani, E., Galetti, M., Fumarola, C., Bonelli, M. A., Cavazzoni, A., Cretella, D., Sirangelo, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078656 · Cited by 52
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
Sin, T. K., Wang, F., Meng, F., Wong, S. C. C., Cho, W. C. S., Siu, P. M., Chan, L., & Yung, B. Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020237 · Cited by 50
Dey, N., Leyland-Jones, B. R., & De, P. K. (2015) · Europe PMC (PubMed Central) · Cited by 50
Zhang, X., Maity, T. K., Kashyap, M. K., Bansal, M., Venugopalan, A. K., Singh, S., Awasthi, S., Marimuthu, A., Jacob, H. K. C., Belkina, N., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m117.067439 · Cited by 50
Yang, S., Lin, C., Stehr, H., Long, S., Kong, C. S., Berry, G. J., Zehnder, J. L., & Kunder, C. A. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.10.007 · Cited by 50
Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
Ark, A. V., Cao, J., & Li, X. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00180 · Cited by 50
Cheng, H., Ge, X., Zhuo, S., Gao, Y., Zhu, B., Zhang, J., Shang, W., Xu, D., Ge, W., & Shi, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01413 · Cited by 51
Grassberger, C., McClatchy, D. M., Geng, C., Kamran, S. C., Fintelmann, F. J., Maruvka, Y. E., Piotrowska, Z., Willers, H., Sequist, L. V. D., Hata, A. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3652 · Cited by 52
Self-citationSuda, K., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355243 · Cited by 49
Lee, K.-K., Kim, Y., Jung, H. A., Lee, S., Ahn, J. S., Ahn, M., Park, K., Choi, Y., & Sun, J. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.012 · Cited by 49
Marin-Acevedo, J. A., Pellini, B., Kimbrough, E. O., Hicks, J. K., & Chiappori, A. (2023) · Cancers · doi:10.3390/cancers15030629 · Cited by 52
Unraveling Tumor Grading and Genomic Landscape in Lung Neuroendocrine Tumors
Pelosi, G., Papotti, M. G., Rindi, G., & Scarpa, A. (2014) · Endocrine Pathology · doi:10.1007/s12022-014-9320-0 · Cited by 49
Sakuma, Y., Matsukuma, S., Nakamura, Y., Yoshihara, M., Koizume, S., Sekiguchi, H., Saito, H., Nakayama, H., Kameda, Y., Yokose, T., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.102 · Cited by 49
Overcoming treatment resistance in cancer: Current understanding and tactics
Wu, G. J., Wilson, G., George, J., Liddle, C., Hebbard, L., & Qiao, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.018 · Cited by 49
Zhang, X., Zhang, Y., Wang, Y., Gupta, P., Zeng, L., Xu, M., Wang, X., Yang, D., & Chen, Z. (2016) · Molecules · doi:10.3390/molecules21091236 · Cited by 49
Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
Imakita, T., Fujita, K., Kanai, O., Terashima, T., & Mio, T. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.03.019 · Cited by 49
Progress in the Management of Advanced Thoracic Malignancies in 2017
Ferrara, R., Mezquita, L., & Besse, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.002 · Cited by 50
Evrard, S., Clermont, E., Rouquette, I., Murray, S. J., Dintner, S., Nam‐Apostolopoulos, Y., Bellosillo, B., Varela, M., Nadal, E., Wiedorn, K. H., et al. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.010 · Cited by 49
Lettig, L., Sahnane, N., Pepe, F., Cerutti, R., Albeni, C., Franzi, F., Veronesi, G., Ogliari, F. R., Pastore, A., Tuzi, A., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.18 · Cited by 51
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Fujino, T., Suda, K., & Mitsudomi, T. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1791821 · Cited by 49
Medical management of brain metastases
Lauko, A. J., Rauf, Y., & Ahluwalia, M. S. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa015 · Cited by 51
Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence
Walens, A., Lin, J., Damrauer, J. S., McKinney, B. J., Lupo, R., Newcomb, R., Fox, D. B., Mabe, N. W., Gresham, J. S., Sheng, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18730-z · Cited by 52
Zeng, Y., Yu, D., Tian, W., & Wu, F. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000805 · Cited by 52
Pharmacodynamic Biomarkers: Falling Short of the Mark?
Gainor, J. F., Longo, D. L., & Chabner, B. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3132 · Cited by 51
Xie, C., Jin, J., Bao, X., Zhan, W.-H., Han, T.-Y., Gan, M., Zhang, C., & Wang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.6311 · Cited by 47
Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis
Yauch, R. L., & Settleman, J. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.01.003 · Cited by 48
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Jotte, R. M., & Spigel, D. R. (2015) · Cancer Medicine · doi:10.1002/cam4.506 · Cited by 51
The pharmacological point of view of resistance to therapy in tumors
Damia, G. L. M., & Garattini, S. K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.008 · Cited by 48
Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
Tang, M., Wu, M., Hwang, M.-H., Chang, Y.-T., Huang, H.-J., Lin, A. M.-Y., & Yang, J. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119135 · Cited by 48
Bonavida, B. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014011929 · Cited by 48
Janne, P. A., Cohen, R. B., Laird, A., Macé, S., Engelman, J. A., Ruiz-Soto, R., Rockich, K. T., Xu, J., Shapiro, G. I., Martínez, P., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000088 · Cited by 49
Self-citationToyokawa, G., Taguchi, K., Ohba, T., Morodomi, Y., Takenaka, T., Hirai, F., Yamaguchi, M., Seto, T., Takenoyama, M., Sugio, K., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182762bcb · Cited by 48
Sun, L., Burnett, J., Gasparyan, M., Xu, F., Jiang, H., Lin, C.-C. A., Myers, I., Körkaya, H., Liu, Y., Connarn, J. N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9839 · Cited by 49
Tsakonas, G., Petris, L. D., & Ekman, S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.004 · Cited by 48
Liao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.009 · Cited by 48
Metadata
- Authors
- Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., Akhavanfard, S., Heist, R. S., Temel, J., Christensen, J. G., Wain, J. C., Lynch, T. J., Vernovsky, K., Mark, E. J., Lanuti, M., Iafrate, A. J., Mino-Kenudson, M., & Engelman, J. A.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Yale Cancer Center (US)
- Pfizer (United States) (US)
- Corresponding author
- Sequist, Lecia V.
- Waltman, Belinda A.
- Dias-Santagata, Dora
- Engelman, Jeffrey A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2011-03-23
- Volume
- 3
- Issue
- 75
- Pages
- 75ra26-75ra26
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC3132801
- OpenAlex
- W1980497534
- Cited by
- 3,499
- References
- 64
- Citations by year
- 2026: 95 · 2025: 141 · 2024: 160 · 2023: 178 · 2022: 249 · 2021: 265 · 2020: 281 · 2019: 259 · 2018: 298 · 2017: 331 · 2016: 279 · 2015: 270 · 2014: 232 · 2013: 253 · 2012: 154
- FWCI
- 188.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA127003, U01CA141457, K08 GRANT CA120060-01, R01CA140594, R21CA156000, P50CA090578, P20CA090578, K08CA120060, R01CA137008)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibitors, drug resistance, non-small cell lung cancer, EGFR mutation, T790M mutation, MET amplification, EGFR amplification, PIK3CA mutation, epithelial-mesenchymal transition, small cell lung cancer transformation, histological evolution, serial biopsies, tyrosine kinase inhibitors
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Biopsy, Female, Genotype, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Phenotype, Quinazolines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
